The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
Recruiting
This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blo... Read More
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
07/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
PerQdisc Traditional Feasibility Trial.
Recruiting
This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label. After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/24/2025
Locations: HOPE Research Institute, Glendale, Arizona +5 locations
Conditions: Discogenic Low Back Pain
GLP-1s to Enhance Lasting Optimal Weight
Recruiting
The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in person or video conference, attend group intervention sessions twice a month via video conference, weigh daily with a study-provided smart scale, keep a record of all foods and beverages consumed, and use... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Obesity
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Recruiting
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/24/2025
Locations: University of Minnesota, Minneapolis, Minnesota +15 locations
Conditions: Phosphomannomutase 2 Deficiency, PMM2-CDG
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
Recruiting
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/24/2025
Locations: Stanford University School of Medicine, Dermatology, Redwood City, California +3 locations
Conditions: Dystrophic Epidermolysis Bullosa
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations
Conditions: Breast Neoplasms
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Recruiting
The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) in adults. Participants will have a 50/50 or 1 out of 2 chance of being placed in the treatment or control arm. The control arm of the study involves PVI alone for ablation procedure(s). The treatment arm involves the use of vMap mapping in addition to PVI to plan ablation procedure(s).
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/24/2025
Locations: Baptist Health Jacksonville, Jacksonville, Florida +7 locations
Conditions: Atrial Fibrillation (AF)
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D
Recruiting
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
07/24/2025
Locations: University of Virginia Center for Diabetes Technology, Charlottesville, Virginia
Conditions: Type 1 Diabetes
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Recruiting
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Exelixis Clinical Site #1, Hickory, North Carolina +2 locations
Conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Apple Health Study
Recruiting
The Apple Health Study aims to build a diverse and inclusive group of participants to help researchers advance our understanding of how signals and information collected from apps and devices relate to health and may be used to predict, detect, monitor, and manage changes in health. To enroll, US residents who have an iPhone can download the Apple Research app from the App Store and go through the introduction and informed consent for the Apple Health Study. This study is fully remote, and all... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: MCRA, Washington, District of Columbia +1 locations
Conditions: Mental Health, Sleep, Exercise, Hormones, Metabolic Health, Hearing, Aging, Lifestyle Factors, Functional Capacity, Neurological Conditions, General Health, Wellbeing, Women's Health
Two Versus One Week Breast Radiotherapy (RT)
Recruiting
This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment do... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
07/24/2025
Locations: Brooklyn Methodist Hospital, New York, New York +2 locations
Conditions: Breast Cancer
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Recruiting
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoa... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/24/2025
Locations: Academic Medical Research Institute, Los Angeles, California +3 locations
Conditions: Primary Membranous Nephropathy